



Gothenburg, 24 July 2017

PRESS RELEASE FLUICELL AB

FLUICELL RECEIVES A NEW PATENT ACCEPTANCE FOR THE BIOPEN SYSTEM

Fluicell AB, a pioneering high-tech company in single-cell biology, is extremely delighted to announce the issuance of US Patent No 9,6719,671,366, entitled “Pipettes, methods of use, and methods of stimulating an object of interest”, by the USPTO.

This is the third patent issued to Fluicell AB, representing a continued advancement of their innovative BioPen system. This platform facilitates complex cell biology experiments at the single-cell level, at affordable prices.

This approval gives further recognition to the Fluicell team as innovation leaders, and solution providers for cell biology research and discovery tools for the 21st century.

About Fluicell

Fluicell is a Swedish biotech company that brings inspiration and innovation to life-science researchers around the globe. Fluicell provides innovative tools with outstanding performance, redefining approaches within; cell biology, biophysics and secondary drug screening and discovery. Fluicell strives for technology solutions which are environmentally friendly, sustainable, and that ultimately reduces costs, resources, and minimizes the use of animals. Fluicell’s main target sectors include universities, the pharmaceutical industry, and national health laboratories.

For further information, visit www.fluicell.com or contact:

Victoire Viannay CEO, Fluicell

Email: victoire@fluicell.com